Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases
Abstract Histone deacetylase inhibitors reside among the most promising targeted anticancer agents that are potent inducers of growth arrest, differentiation, and/or apoptotic cell death of transformed cells. In October 2006, the US Food and Drug Administration approved the first drug of this new cl...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Riester, Daniel [verfasserIn] |
|---|
| Format: |
Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2007 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Springer-Verlag 2007 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Applied microbiology and biotechnology - Springer Berlin Heidelberg, 1984, 75(2007), 3 vom: 22. März, Seite 499-514 |
|---|---|
| Übergeordnetes Werk: |
volume:75 ; year:2007 ; number:3 ; day:22 ; month:03 ; pages:499-514 |
| Links: |
|---|
| DOI / URN: |
10.1007/s00253-007-0912-1 |
|---|
| Katalog-ID: |
OLC2050713045 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2050713045 | ||
| 003 | DE-627 | ||
| 005 | 20230510073156.0 | ||
| 007 | tu | ||
| 008 | 200820s2007 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00253-007-0912-1 |2 doi | |
| 035 | |a (DE-627)OLC2050713045 | ||
| 035 | |a (DE-He213)s00253-007-0912-1-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a 12 |2 ssgn | ||
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 100 | 1 | |a Riester, Daniel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases |
| 264 | 1 | |c 2007 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer-Verlag 2007 | ||
| 520 | |a Abstract Histone deacetylase inhibitors reside among the most promising targeted anticancer agents that are potent inducers of growth arrest, differentiation, and/or apoptotic cell death of transformed cells. In October 2006, the US Food and Drug Administration approved the first drug of this new class, vorinostat (1, Zolinza, Merck). Several histone deacetylase (HDAC) inhibitors more are in clinical trials. HDAC inhibitors have shown significant activity against a variety of hematological and solid tumors at doses that are well tolerated by patients, both in monotherapy as well as in combination therapy with other drugs. This paper reviews the most recent developments in HDAC inhibitor design, particularly in the context of anticancer therapy, and other possible pharmaceutical applications. | ||
| 650 | 4 | |a Histone deacetylase inhibitors | |
| 650 | 4 | |a Epigenetics | |
| 650 | 4 | |a Cancer drug design | |
| 650 | 4 | |a Hydroxamates | |
| 650 | 4 | |a Benzamides | |
| 650 | 4 | |a Clinical trials | |
| 700 | 1 | |a Hildmann, Christian |4 aut | |
| 700 | 1 | |a Schwienhorst, Andreas |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Applied microbiology and biotechnology |d Springer Berlin Heidelberg, 1984 |g 75(2007), 3 vom: 22. März, Seite 499-514 |w (DE-627)129942634 |w (DE-600)392453-1 |w (DE-576)015507750 |x 0175-7598 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2007 |g number:3 |g day:22 |g month:03 |g pages:499-514 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00253-007-0912-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-TEC | ||
| 912 | |a SSG-OLC-CHE | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_21 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_130 | ||
| 912 | |a GBV_ILN_147 | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_2360 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4082 | ||
| 912 | |a GBV_ILN_4277 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4307 | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2007 |e 3 |b 22 |c 03 |h 499-514 | ||
| author_variant |
d r dr c h ch a s as |
|---|---|
| matchkey_str |
article:01757598:2007----::itndaeyaeniiosunneieimcaimognrgltoittosfhrpuiitr |
| hierarchy_sort_str |
2007 |
| publishDate |
2007 |
| allfields |
10.1007/s00253-007-0912-1 doi (DE-627)OLC2050713045 (DE-He213)s00253-007-0912-1-p DE-627 ger DE-627 rakwb eng 570 VZ 12 ssgn BIODIV DE-30 fid Riester, Daniel verfasserin aut Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases 2007 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Springer-Verlag 2007 Abstract Histone deacetylase inhibitors reside among the most promising targeted anticancer agents that are potent inducers of growth arrest, differentiation, and/or apoptotic cell death of transformed cells. In October 2006, the US Food and Drug Administration approved the first drug of this new class, vorinostat (1, Zolinza, Merck). Several histone deacetylase (HDAC) inhibitors more are in clinical trials. HDAC inhibitors have shown significant activity against a variety of hematological and solid tumors at doses that are well tolerated by patients, both in monotherapy as well as in combination therapy with other drugs. This paper reviews the most recent developments in HDAC inhibitor design, particularly in the context of anticancer therapy, and other possible pharmaceutical applications. Histone deacetylase inhibitors Epigenetics Cancer drug design Hydroxamates Benzamides Clinical trials Hildmann, Christian aut Schwienhorst, Andreas aut Enthalten in Applied microbiology and biotechnology Springer Berlin Heidelberg, 1984 75(2007), 3 vom: 22. März, Seite 499-514 (DE-627)129942634 (DE-600)392453-1 (DE-576)015507750 0175-7598 nnns volume:75 year:2007 number:3 day:22 month:03 pages:499-514 https://doi.org/10.1007/s00253-007-0912-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC FID-BIODIV SSG-OLC-TEC SSG-OLC-CHE SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_21 GBV_ILN_23 GBV_ILN_40 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_100 GBV_ILN_130 GBV_ILN_147 GBV_ILN_267 GBV_ILN_285 GBV_ILN_2004 GBV_ILN_2018 GBV_ILN_2360 GBV_ILN_4012 GBV_ILN_4082 GBV_ILN_4277 GBV_ILN_4305 GBV_ILN_4307 AR 75 2007 3 22 03 499-514 |
| spelling |
10.1007/s00253-007-0912-1 doi (DE-627)OLC2050713045 (DE-He213)s00253-007-0912-1-p DE-627 ger DE-627 rakwb eng 570 VZ 12 ssgn BIODIV DE-30 fid Riester, Daniel verfasserin aut Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases 2007 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Springer-Verlag 2007 Abstract Histone deacetylase inhibitors reside among the most promising targeted anticancer agents that are potent inducers of growth arrest, differentiation, and/or apoptotic cell death of transformed cells. In October 2006, the US Food and Drug Administration approved the first drug of this new class, vorinostat (1, Zolinza, Merck). Several histone deacetylase (HDAC) inhibitors more are in clinical trials. HDAC inhibitors have shown significant activity against a variety of hematological and solid tumors at doses that are well tolerated by patients, both in monotherapy as well as in combination therapy with other drugs. This paper reviews the most recent developments in HDAC inhibitor design, particularly in the context of anticancer therapy, and other possible pharmaceutical applications. Histone deacetylase inhibitors Epigenetics Cancer drug design Hydroxamates Benzamides Clinical trials Hildmann, Christian aut Schwienhorst, Andreas aut Enthalten in Applied microbiology and biotechnology Springer Berlin Heidelberg, 1984 75(2007), 3 vom: 22. März, Seite 499-514 (DE-627)129942634 (DE-600)392453-1 (DE-576)015507750 0175-7598 nnns volume:75 year:2007 number:3 day:22 month:03 pages:499-514 https://doi.org/10.1007/s00253-007-0912-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC FID-BIODIV SSG-OLC-TEC SSG-OLC-CHE SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_21 GBV_ILN_23 GBV_ILN_40 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_100 GBV_ILN_130 GBV_ILN_147 GBV_ILN_267 GBV_ILN_285 GBV_ILN_2004 GBV_ILN_2018 GBV_ILN_2360 GBV_ILN_4012 GBV_ILN_4082 GBV_ILN_4277 GBV_ILN_4305 GBV_ILN_4307 AR 75 2007 3 22 03 499-514 |
| allfields_unstemmed |
10.1007/s00253-007-0912-1 doi (DE-627)OLC2050713045 (DE-He213)s00253-007-0912-1-p DE-627 ger DE-627 rakwb eng 570 VZ 12 ssgn BIODIV DE-30 fid Riester, Daniel verfasserin aut Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases 2007 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Springer-Verlag 2007 Abstract Histone deacetylase inhibitors reside among the most promising targeted anticancer agents that are potent inducers of growth arrest, differentiation, and/or apoptotic cell death of transformed cells. In October 2006, the US Food and Drug Administration approved the first drug of this new class, vorinostat (1, Zolinza, Merck). Several histone deacetylase (HDAC) inhibitors more are in clinical trials. HDAC inhibitors have shown significant activity against a variety of hematological and solid tumors at doses that are well tolerated by patients, both in monotherapy as well as in combination therapy with other drugs. This paper reviews the most recent developments in HDAC inhibitor design, particularly in the context of anticancer therapy, and other possible pharmaceutical applications. Histone deacetylase inhibitors Epigenetics Cancer drug design Hydroxamates Benzamides Clinical trials Hildmann, Christian aut Schwienhorst, Andreas aut Enthalten in Applied microbiology and biotechnology Springer Berlin Heidelberg, 1984 75(2007), 3 vom: 22. März, Seite 499-514 (DE-627)129942634 (DE-600)392453-1 (DE-576)015507750 0175-7598 nnns volume:75 year:2007 number:3 day:22 month:03 pages:499-514 https://doi.org/10.1007/s00253-007-0912-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC FID-BIODIV SSG-OLC-TEC SSG-OLC-CHE SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_21 GBV_ILN_23 GBV_ILN_40 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_100 GBV_ILN_130 GBV_ILN_147 GBV_ILN_267 GBV_ILN_285 GBV_ILN_2004 GBV_ILN_2018 GBV_ILN_2360 GBV_ILN_4012 GBV_ILN_4082 GBV_ILN_4277 GBV_ILN_4305 GBV_ILN_4307 AR 75 2007 3 22 03 499-514 |
| allfieldsGer |
10.1007/s00253-007-0912-1 doi (DE-627)OLC2050713045 (DE-He213)s00253-007-0912-1-p DE-627 ger DE-627 rakwb eng 570 VZ 12 ssgn BIODIV DE-30 fid Riester, Daniel verfasserin aut Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases 2007 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Springer-Verlag 2007 Abstract Histone deacetylase inhibitors reside among the most promising targeted anticancer agents that are potent inducers of growth arrest, differentiation, and/or apoptotic cell death of transformed cells. In October 2006, the US Food and Drug Administration approved the first drug of this new class, vorinostat (1, Zolinza, Merck). Several histone deacetylase (HDAC) inhibitors more are in clinical trials. HDAC inhibitors have shown significant activity against a variety of hematological and solid tumors at doses that are well tolerated by patients, both in monotherapy as well as in combination therapy with other drugs. This paper reviews the most recent developments in HDAC inhibitor design, particularly in the context of anticancer therapy, and other possible pharmaceutical applications. Histone deacetylase inhibitors Epigenetics Cancer drug design Hydroxamates Benzamides Clinical trials Hildmann, Christian aut Schwienhorst, Andreas aut Enthalten in Applied microbiology and biotechnology Springer Berlin Heidelberg, 1984 75(2007), 3 vom: 22. März, Seite 499-514 (DE-627)129942634 (DE-600)392453-1 (DE-576)015507750 0175-7598 nnns volume:75 year:2007 number:3 day:22 month:03 pages:499-514 https://doi.org/10.1007/s00253-007-0912-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC FID-BIODIV SSG-OLC-TEC SSG-OLC-CHE SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_21 GBV_ILN_23 GBV_ILN_40 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_100 GBV_ILN_130 GBV_ILN_147 GBV_ILN_267 GBV_ILN_285 GBV_ILN_2004 GBV_ILN_2018 GBV_ILN_2360 GBV_ILN_4012 GBV_ILN_4082 GBV_ILN_4277 GBV_ILN_4305 GBV_ILN_4307 AR 75 2007 3 22 03 499-514 |
| allfieldsSound |
10.1007/s00253-007-0912-1 doi (DE-627)OLC2050713045 (DE-He213)s00253-007-0912-1-p DE-627 ger DE-627 rakwb eng 570 VZ 12 ssgn BIODIV DE-30 fid Riester, Daniel verfasserin aut Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases 2007 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Springer-Verlag 2007 Abstract Histone deacetylase inhibitors reside among the most promising targeted anticancer agents that are potent inducers of growth arrest, differentiation, and/or apoptotic cell death of transformed cells. In October 2006, the US Food and Drug Administration approved the first drug of this new class, vorinostat (1, Zolinza, Merck). Several histone deacetylase (HDAC) inhibitors more are in clinical trials. HDAC inhibitors have shown significant activity against a variety of hematological and solid tumors at doses that are well tolerated by patients, both in monotherapy as well as in combination therapy with other drugs. This paper reviews the most recent developments in HDAC inhibitor design, particularly in the context of anticancer therapy, and other possible pharmaceutical applications. Histone deacetylase inhibitors Epigenetics Cancer drug design Hydroxamates Benzamides Clinical trials Hildmann, Christian aut Schwienhorst, Andreas aut Enthalten in Applied microbiology and biotechnology Springer Berlin Heidelberg, 1984 75(2007), 3 vom: 22. März, Seite 499-514 (DE-627)129942634 (DE-600)392453-1 (DE-576)015507750 0175-7598 nnns volume:75 year:2007 number:3 day:22 month:03 pages:499-514 https://doi.org/10.1007/s00253-007-0912-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC FID-BIODIV SSG-OLC-TEC SSG-OLC-CHE SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_21 GBV_ILN_23 GBV_ILN_40 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_100 GBV_ILN_130 GBV_ILN_147 GBV_ILN_267 GBV_ILN_285 GBV_ILN_2004 GBV_ILN_2018 GBV_ILN_2360 GBV_ILN_4012 GBV_ILN_4082 GBV_ILN_4277 GBV_ILN_4305 GBV_ILN_4307 AR 75 2007 3 22 03 499-514 |
| language |
English |
| source |
Enthalten in Applied microbiology and biotechnology 75(2007), 3 vom: 22. März, Seite 499-514 volume:75 year:2007 number:3 day:22 month:03 pages:499-514 |
| sourceStr |
Enthalten in Applied microbiology and biotechnology 75(2007), 3 vom: 22. März, Seite 499-514 volume:75 year:2007 number:3 day:22 month:03 pages:499-514 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Histone deacetylase inhibitors Epigenetics Cancer drug design Hydroxamates Benzamides Clinical trials |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
Applied microbiology and biotechnology |
| authorswithroles_txt_mv |
Riester, Daniel @@aut@@ Hildmann, Christian @@aut@@ Schwienhorst, Andreas @@aut@@ |
| publishDateDaySort_date |
2007-03-22T00:00:00Z |
| hierarchy_top_id |
129942634 |
| dewey-sort |
3570 |
| id |
OLC2050713045 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">OLC2050713045</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230510073156.0</controlfield><controlfield tag="007">tu</controlfield><controlfield tag="008">200820s2007 xx ||||| 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00253-007-0912-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)OLC2050713045</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-He213)s00253-007-0912-1-p</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">12</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Riester, Daniel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">ohne Hilfsmittel zu benutzen</subfield><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Band</subfield><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Springer-Verlag 2007</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Histone deacetylase inhibitors reside among the most promising targeted anticancer agents that are potent inducers of growth arrest, differentiation, and/or apoptotic cell death of transformed cells. In October 2006, the US Food and Drug Administration approved the first drug of this new class, vorinostat (1, Zolinza, Merck). Several histone deacetylase (HDAC) inhibitors more are in clinical trials. HDAC inhibitors have shown significant activity against a variety of hematological and solid tumors at doses that are well tolerated by patients, both in monotherapy as well as in combination therapy with other drugs. This paper reviews the most recent developments in HDAC inhibitor design, particularly in the context of anticancer therapy, and other possible pharmaceutical applications.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Histone deacetylase inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Epigenetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer drug design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hydroxamates</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Benzamides</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clinical trials</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hildmann, Christian</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schwienhorst, Andreas</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Applied microbiology and biotechnology</subfield><subfield code="d">Springer Berlin Heidelberg, 1984</subfield><subfield code="g">75(2007), 3 vom: 22. März, Seite 499-514</subfield><subfield code="w">(DE-627)129942634</subfield><subfield code="w">(DE-600)392453-1</subfield><subfield code="w">(DE-576)015507750</subfield><subfield code="x">0175-7598</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:75</subfield><subfield code="g">year:2007</subfield><subfield code="g">number:3</subfield><subfield code="g">day:22</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:499-514</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">https://doi.org/10.1007/s00253-007-0912-1</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_OLC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-TEC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-CHE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-DE-84</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_21</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_130</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2360</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4082</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4277</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">75</subfield><subfield code="j">2007</subfield><subfield code="e">3</subfield><subfield code="b">22</subfield><subfield code="c">03</subfield><subfield code="h">499-514</subfield></datafield></record></collection>
|
| author |
Riester, Daniel |
| spellingShingle |
Riester, Daniel ddc 570 ssgn 12 fid BIODIV misc Histone deacetylase inhibitors misc Epigenetics misc Cancer drug design misc Hydroxamates misc Benzamides misc Clinical trials Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases |
| authorStr |
Riester, Daniel |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)129942634 |
| format |
Article |
| dewey-ones |
570 - Life sciences; biology |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
OLC |
| remote_str |
false |
| illustrated |
Not Illustrated |
| issn |
0175-7598 |
| topic_title |
570 VZ 12 ssgn BIODIV DE-30 fid Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases Histone deacetylase inhibitors Epigenetics Cancer drug design Hydroxamates Benzamides Clinical trials |
| topic |
ddc 570 ssgn 12 fid BIODIV misc Histone deacetylase inhibitors misc Epigenetics misc Cancer drug design misc Hydroxamates misc Benzamides misc Clinical trials |
| topic_unstemmed |
ddc 570 ssgn 12 fid BIODIV misc Histone deacetylase inhibitors misc Epigenetics misc Cancer drug design misc Hydroxamates misc Benzamides misc Clinical trials |
| topic_browse |
ddc 570 ssgn 12 fid BIODIV misc Histone deacetylase inhibitors misc Epigenetics misc Cancer drug design misc Hydroxamates misc Benzamides misc Clinical trials |
| format_facet |
Aufsätze Gedruckte Aufsätze |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
nc |
| hierarchy_parent_title |
Applied microbiology and biotechnology |
| hierarchy_parent_id |
129942634 |
| dewey-tens |
570 - Life sciences; biology |
| hierarchy_top_title |
Applied microbiology and biotechnology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)129942634 (DE-600)392453-1 (DE-576)015507750 |
| title |
Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases |
| ctrlnum |
(DE-627)OLC2050713045 (DE-He213)s00253-007-0912-1-p |
| title_full |
Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases |
| author_sort |
Riester, Daniel |
| journal |
Applied microbiology and biotechnology |
| journalStr |
Applied microbiology and biotechnology |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2007 |
| contenttype_str_mv |
txt |
| container_start_page |
499 |
| author_browse |
Riester, Daniel Hildmann, Christian Schwienhorst, Andreas |
| container_volume |
75 |
| class |
570 VZ 12 ssgn BIODIV DE-30 fid |
| format_se |
Aufsätze |
| author-letter |
Riester, Daniel |
| doi_str_mv |
10.1007/s00253-007-0912-1 |
| dewey-full |
570 |
| title_sort |
histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases |
| title_auth |
Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases |
| abstract |
Abstract Histone deacetylase inhibitors reside among the most promising targeted anticancer agents that are potent inducers of growth arrest, differentiation, and/or apoptotic cell death of transformed cells. In October 2006, the US Food and Drug Administration approved the first drug of this new class, vorinostat (1, Zolinza, Merck). Several histone deacetylase (HDAC) inhibitors more are in clinical trials. HDAC inhibitors have shown significant activity against a variety of hematological and solid tumors at doses that are well tolerated by patients, both in monotherapy as well as in combination therapy with other drugs. This paper reviews the most recent developments in HDAC inhibitor design, particularly in the context of anticancer therapy, and other possible pharmaceutical applications. © Springer-Verlag 2007 |
| abstractGer |
Abstract Histone deacetylase inhibitors reside among the most promising targeted anticancer agents that are potent inducers of growth arrest, differentiation, and/or apoptotic cell death of transformed cells. In October 2006, the US Food and Drug Administration approved the first drug of this new class, vorinostat (1, Zolinza, Merck). Several histone deacetylase (HDAC) inhibitors more are in clinical trials. HDAC inhibitors have shown significant activity against a variety of hematological and solid tumors at doses that are well tolerated by patients, both in monotherapy as well as in combination therapy with other drugs. This paper reviews the most recent developments in HDAC inhibitor design, particularly in the context of anticancer therapy, and other possible pharmaceutical applications. © Springer-Verlag 2007 |
| abstract_unstemmed |
Abstract Histone deacetylase inhibitors reside among the most promising targeted anticancer agents that are potent inducers of growth arrest, differentiation, and/or apoptotic cell death of transformed cells. In October 2006, the US Food and Drug Administration approved the first drug of this new class, vorinostat (1, Zolinza, Merck). Several histone deacetylase (HDAC) inhibitors more are in clinical trials. HDAC inhibitors have shown significant activity against a variety of hematological and solid tumors at doses that are well tolerated by patients, both in monotherapy as well as in combination therapy with other drugs. This paper reviews the most recent developments in HDAC inhibitor design, particularly in the context of anticancer therapy, and other possible pharmaceutical applications. © Springer-Verlag 2007 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_OLC FID-BIODIV SSG-OLC-TEC SSG-OLC-CHE SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_21 GBV_ILN_23 GBV_ILN_40 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_100 GBV_ILN_130 GBV_ILN_147 GBV_ILN_267 GBV_ILN_285 GBV_ILN_2004 GBV_ILN_2018 GBV_ILN_2360 GBV_ILN_4012 GBV_ILN_4082 GBV_ILN_4277 GBV_ILN_4305 GBV_ILN_4307 |
| container_issue |
3 |
| title_short |
Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases |
| url |
https://doi.org/10.1007/s00253-007-0912-1 |
| remote_bool |
false |
| author2 |
Hildmann, Christian Schwienhorst, Andreas |
| author2Str |
Hildmann, Christian Schwienhorst, Andreas |
| ppnlink |
129942634 |
| mediatype_str_mv |
n |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s00253-007-0912-1 |
| up_date |
2024-07-04T02:39:37.409Z |
| _version_ |
1803614449734516736 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">OLC2050713045</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230510073156.0</controlfield><controlfield tag="007">tu</controlfield><controlfield tag="008">200820s2007 xx ||||| 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00253-007-0912-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)OLC2050713045</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-He213)s00253-007-0912-1-p</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">12</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Riester, Daniel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">ohne Hilfsmittel zu benutzen</subfield><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Band</subfield><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Springer-Verlag 2007</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Histone deacetylase inhibitors reside among the most promising targeted anticancer agents that are potent inducers of growth arrest, differentiation, and/or apoptotic cell death of transformed cells. In October 2006, the US Food and Drug Administration approved the first drug of this new class, vorinostat (1, Zolinza, Merck). Several histone deacetylase (HDAC) inhibitors more are in clinical trials. HDAC inhibitors have shown significant activity against a variety of hematological and solid tumors at doses that are well tolerated by patients, both in monotherapy as well as in combination therapy with other drugs. This paper reviews the most recent developments in HDAC inhibitor design, particularly in the context of anticancer therapy, and other possible pharmaceutical applications.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Histone deacetylase inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Epigenetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer drug design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hydroxamates</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Benzamides</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clinical trials</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hildmann, Christian</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schwienhorst, Andreas</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Applied microbiology and biotechnology</subfield><subfield code="d">Springer Berlin Heidelberg, 1984</subfield><subfield code="g">75(2007), 3 vom: 22. März, Seite 499-514</subfield><subfield code="w">(DE-627)129942634</subfield><subfield code="w">(DE-600)392453-1</subfield><subfield code="w">(DE-576)015507750</subfield><subfield code="x">0175-7598</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:75</subfield><subfield code="g">year:2007</subfield><subfield code="g">number:3</subfield><subfield code="g">day:22</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:499-514</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">https://doi.org/10.1007/s00253-007-0912-1</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_OLC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-TEC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-CHE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-DE-84</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_21</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_130</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2360</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4082</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4277</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">75</subfield><subfield code="j">2007</subfield><subfield code="e">3</subfield><subfield code="b">22</subfield><subfield code="c">03</subfield><subfield code="h">499-514</subfield></datafield></record></collection>
|
| score |
7.40158 |